Medical Newswire

Medical Newswire!

Medicine, Healthcare, Medical Research, Hospitals, Management
Press release distribution service
Home | Medical-Newswire.Com:

VFC's Stock House: NovaBay (NBY) May Be Highly Undervalued

(EMAILWIRE.COM, March 21, 2012 ) New York, NY -- NovaBay Pharmaceuticals (NBY) released news this week that offers to broaden the scope and reach of the company's Aganocide compounds, which are being positioned as anti-infectives and could potentially replace modern day antibiotics as resistance to such treatment grows.

On Tuesday NovaBay announced a deal with Virbac Animal Health to bring its technology to the veterinary market. According to the agreement, NovaBay will receive an upfront payment - and some additional support for research and development - while Virbac will retain the option to license any of the Aganocide compounds that are successfully applied to treating veterinary indications.

The deal could provide NovaBay with a steady revenue stream in the future if Virbac exercises its licensing option. According to the Tuesday press release, if the option is exercised,

"NovaBay may receive additional payments, which include an exercise fee as well as development and pre-commercial milestones for a line of veterinary products. NovaBay will also receive royalties on sales of any successfully commercialized Aganocide products to arise from this agreement."

Few companies are going to become superpowers in the field of medicine on treating veterinary indications alone, but the deal brings some attention back to NovaBay and gives us another chance to consider this company's technology on the open market - should the pipeline products make it that far.

It also gives us the opportunity to determine whether or not the current market capitalization for NBY justifies that pipeline potential, which, in the opinion of this writer, the determination is "probably not."

First, let's revisit the problem of antibiotic resistance.

When introduced into society seventy years ago, antibiotics changed the shape of medicine, and provided what - at the time - was considered a huge leap forward in treating bacterial infections. Having been so widely-used since then, however, the infectious organisms against which the antibiotics are administered have grown increasingly resistant, and sometimes immune, to today's antibiotic treatments.

The Centers for Disease Control and Prevention considers the developing resistance to antibiotics as a "crisis", noting on its website that, "These drugs have been used so widely and for so long that the infectious organisms the antibiotics are designed to kill have adapted to them, making the drugs less effective. People infected with antimicrobial-resistant organisms are more likely to have longer, more expensive hospital stays, and may be more likely to die as a result of the infection."

Medical professionals themselves understand the growing risks associated with antibiotic resistance, as noted by Dr. Marc Siegel, associate professor of medicine and medical director of Doctor Radio at NYU Langone Medical Center, this week in an article published on FoxNews.com. Dr. Siegel also notes that Doctors continue to over prescribe these treatments, thereby strengthening the resistance of the surviving bacteria and creating new "super colonies" that will eventually be uncontrollable.

This dilemma has created a huge monetary burden on the global health care system and is possibly setting up a one-time "miracle cure" as irrelevant.

That's where NovaBay comes into the picture.

NovaBay has developed, through its proprietary Aganocide compounds, a pipeline of synthetic anti-infectives that are designed to mimic the body's own defenses against infection. Namely, these synthetic molecules, based on the Aganocide compound NVC-422, essentially act in the same manner and processes of a body's white blood cells and not as antibiotics, therefore significantly reducing the risk of a resistance being developed.

The potential of such a technology has market-moving implications, and under the circumstances, it's understandable why NBY could be tagged with an 'undervalued' label.

There are, however, a couple of reasons why investors may not yet have fully embraced the company and its technology. The first reason may be the most obvious one; that NovaBay still has nothing beyond Phase II, and therefore any investment in the company is highly speculative and risky at this point, which is a fair assessment.

That said, the best deals in biotech are the ones that are found early, when patience is needed as the trial results pan out. It's also worth noting, however, that he trend of staying away from speculative "Phase II" investments may be shifting.

Take Lpath, Inc. (LPTN), for example. Lpath also has a novel and potentially groundbreaking technology in the works, but Pfizer (PFI) has bucked the Phase II label of the company and jumped in with a very significant partnership.

CellDex Therapeutics (CLDX) is another one that has traded very highly during its Phase II stages, even when Pfizer decided to divorce itself from a partnership with the company.

In both cases, investors may have started to become clued in to how much market potential is contained within those respective pipelines and tossed the standard "wait until Phase III" strategy to the side. As investors with similar strategies in mind research NovaBay, the same potential for price appreciation exists; especially give the fact that NBY has a powerhouse partner of its own in Galderma SA, with whom NovaBay is developing a treatment for the highly-contagious skin condition, Impetigo.

Another reason why NovaBay may be missing the mark in terms of market cap right now, and this one may be more relevant than the last, is that an earlier clinical trial conducted with then-partner Alcon in the treatment of adenoviral conjunctivits - better known to the average Joe as "pink eye" - failed.

Shares slumped badly after that news hit the presses and have only barely recovered since.

On the flip side to the endpoint miss, however, which sent sent investors running for the doors, is that a further look at the data from the same trial did show that efficacy was demonstrated against Epidemic Keratoconjunctivitis (EKC), possibly the most contagious form of the infection, and which often threatens a victim's vision.

Based on that data, trials have continued, but the fact that the company has a failed trial under its belt most certainly deters some investors from jumping back in, at least until they see more results.

A Phase IIb trial for this indication is expected to begin within months, while another Phase II trial for the Impetigo condition is also slated for this year.

Results from 'Part A' from a trial testing NVC-422 as a treatment for urinary catheter blockage and encrustation (UCBE) have already rolled in, with results from 'Part B' also due within months.

The pending trial results provide some short term catalysts, but another catalyst due for this year could be the one that puts NovaBay on the map.

A commercial launch is planned for the short to mid term for NeutroPhase, NBY's first FDA-cleared product and a treatment for chronic wound in both hospital and personal care. A successful launch for NeutroPhase could alleviate many of the monetary concerns normally associated with a small company bringing its pipeline through trials, and just a couple of months ago the company announced its first strategic partner for NeutroPhase.

Having a product already on the market and bringing in revenue will go a long way to validating this small company in the eyes of potential investors, especially if the NeutroPhase commercial launch goes off without a hitch.

Based on the pending trial catalysts, the commercial launch of NeutroPhase, and most importantly, the potential of NVC-422 products on the open market as eventual substitutes for antibiotics, NBY may still be trading under the radar and could still be lightly valued, when all is considered.

By 2013 the NovaBay could have three Phase III trials ongoing with an FDA approved product on the market.

If that's the case, it's a fair bet to assume that the market cap will be significantly higher than thirty five million at that point.

For an example of how a shift from Phase II to Phase III can effect a market cap, one could look at Keryx BioPharmaceuticals (KERX). During the early to mid stages of Phase II, the KERX market cap was similar to NBY's now, but when Phase II trials were successful and Phase III came along?

Prices quickly quadrupled.

NovaBay's target market of anti-infective care is a multi-multi-billion dollar market annually, and NBY could quickly penetrate that market, as Doctors are currently looking for a way around antibiotic resistance.

As I've previously discussed, this company may be at the right place at the right time. For investors being in the right place at the right time means being "in" before any price run starts, and it's possible that NBY has a ways to move, should the pending catalysts turn out positive.

Disclosure: Long NBY.

For more information and commentary regading NBY, visit: http://vfcsstockhouse.com/blog/article/-novabay-may-be-in-the-right-place-at-the-right-time-with-an-answer-for-antibiotic-resistance

or

http://vfcsstockhouse.com/blog/article/-nby-key-deal-marks-a-year-of-swift-progression

Contact VFC's Stock House: vfc@vfcsstockhouse.com

About VFCsStockHouse.com:

VFC's Stock House offers research-based investment information, insights and ideas on a variety of different companies in numerous sectors, with a focus on biotech stocks and healthcare.

For full reports on Celsius Holdings and other companies visit: http://vfcsstockhouse.com

Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse

'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213

For full disclaimer visit: http://vfcsstockhouse.com


VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com

Source: EmailWire.com


Medical Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Healthcare resource center today to browse our selection of 600+ complimentary Healthcare magazines, white papers, webinars, podcasts, and more. Get popular titles including:

Eyecare Business
Medical Laboratory Observer
FierceHealthcare

No credit cards, coupons, or promo codes required. Try it today!

Medical Sponsors

Health News
Health News Headlines - Yahoo News
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on top health stories.

Menopause tied to faster decline in women?s lung function
6 Dec 2016 at 11:09am
By Lisa Rapaport Age-related decline in women?s lung function may speed up during and after menopause, a recent study suggests. Past research has shown that young women can boost their lung function through their mid-twenties by following a healthy lifestyle that includes getting plenty of aerobic exercise and avoiding cigarettes. After that, lung function declines gradually, and the process can be sped up when people smoke or carry excess fat around their midsection.


Cuba, U.S. to discuss detente in wake of Trump election
6 Dec 2016 at 11:06am

HAVANA/WASHINGTON (Reuters) - Cuba and the United States will draw up a roadmap for deepening their detente, the Cuban government said on Tuesday, in a first meeting since the election of Donald Trump as U.S. president and the death of Cuban revolutionary Fidel Castro. Wednesday's fifth U.S.-Cuban bilateral commission comes at a time of increased uncertainty about the future of U.S.-Cuban relations given Trump's promise to end the detente if Cuba did not offer a better "deal." The administration of outgoing U.S. President Barack Obama has pressed American companies to complete additional business deals in Cuba to help further cement the president?s policy by the time Trump takes office on January 20.


Twin Girls Joined at the Chest to Be Separated in 18-Hour Surgery Today
6 Dec 2016 at 10:54am
Twin 2-year-old girls were born conjoined at chest, abdomen.


Philip Morris seeks U.S. approval to market alternative cigarette
6 Dec 2016 at 10:54am

The company's application is the first to seek U.S. approval to market a tobacco product as being less harmful than traditional cigarettes. If approved by the U.S. Food and Drug Administration, the company's iQOS device could give it a significant marketing advantage over alternatives to tobacco products, including electronic cigarettes, which are not allowed to make such a claim. The device electronically heats tobacco to produce a vapor without burning it, and the company claims the vapor has less than 10 percent of the harmful chemicals found in cigarette smoke.



Senate leader pushes for extension of coal miner healthcare
6 Dec 2016 at 10:44am

U.S. Senate Majority Leader Mitch McConnell on Tuesday said he is pushing to extend expiring healthcare benefits for retired coal miners by including a provision in a spending bill Congress hopes to pass this week. In a statement on the Senate floor, McConnell, a Republican from Kentucky, said that in conversations with House of Representatives Speaker Paul Ryan he has insisted that the Continuing Resolution include "a provision to address that issue so these retirees don't lose their healthcare benefit at the end of this year." The fate of the United Mine Workers' health care and pension funds is up in the air as Congress weighs legislation to provide financial support for the soon-expiring benefits, which are at risk of default as coal companies grapple with bankruptcies.



Mugabe praises resilient Zimbabweans, skirts bond notes
6 Dec 2016 at 10:44am

By MacDonald Dzirutwe HARARE (Reuters) - President Robert Mugabe praised Zimbabweans on Tuesday for resilience in the face of economic hardship, in a speech that avoided the recent introduction of "bond notes", a new currency that has raised fears of uncontrolled money-printing. "Let me conclude by paying tribute to our peace-loving people who have endured all manner of economic hardships since we embarked on the historic land-reform programme," Mugabe said to grumbles from opposition benches and shouts of "bond notes". Critics accuse Mugabe, in power since independence from Britain in 1980, of wrecking one of Africa's most promising economies through policies such as the violent seizure of white-owned commercial farms and disastrous printing of money.


Factbox: Contenders for key jobs in Trump's administration
6 Dec 2016 at 10:09am
(Reuters) - Below are people mentioned as contenders for senior roles as U.S. President-elect Donald Trump works to form his administration before taking office on Jan. 20, according to Reuters sources and media reports. Trump has already tapped a number of people for other top jobs in his administration. For a list of posts already filled, see. SECRETARY OF STATE * Mitt Romney, 2012 Republican presidential nominee and former Massachusetts governor * Rudy Giuliani, Republican former mayor of New York City * Bob Corker, Republican U.S. ...


Environmental group takes De Beers Canada to court over mercury
6 Dec 2016 at 10:07am

(Reuters) - An environmental group said on Tuesday it had filed a lawsuit against De Beers Canada, accusing the diamond producer of failing to report toxic levels of mercury and methylmercury at its Victor Diamond mine in northern Ontario. The Wildlands League alleged that De Beers failed to report mercury levels from five out of nine surface water monitoring stations for the creeks next to its open pit mine between 2009 and 2016. This was an offence under the Ontario Water Resources Act, the group said in a statement.


Historians seek reparations for Californians forcibly sterilized
6 Dec 2016 at 9:04am
In a Sacramento government office, historian and lead author Alexandra Minna Stern stumbled across a filing cabinet containing about 20,000 recommendations for eugenics-motivated sterilizations dating from 1919 through 1952. Stern, a professor at the University of Michigan in Ann Arbor, and her colleagues used the documents and actuarial tables to calculate that as many as 831 men, women and children slated for sterilization could still be alive and would be on average almost 88 years old. Many of the typewritten and signed sterilization recommendations were for children, the youngest 7 years old, Stern said in a phone interview.


One drink a day may not always keep the doctor away
6 Dec 2016 at 8:47am

By Lisa Rapaport (Reuters Health) - It?s called ?holiday heart? because it happens to binge drinkers who feel a flutter or irregular heartbeat after too many cocktails at parties. Conventional wisdom, based on plenty of previous research, is that the occasional glass of wine or beer can be good for the heart, reducing the risk of heart disease and stroke as well as death from cardiovascular causes, lead study author Dr. Peter Kistler of the Baker IDI Heart and Diabetes Institute and the Alfred Hospital in Melbourne, Australia, told Reuters Health. For the current study, however, researchers examined data collected on almost 900,000 people and found an 8 percent risk increase for irregular heartbeat with each alcoholic drink consumed per day.


IUDS, implants may be best birth control for women with diabetes
6 Dec 2016 at 8:41am
By Andrew M. Seaman (Reuters Health) - The two most effective hormonal birth control methods for women in general are also excellent options for women with diabetes, according to a new study. Intrauterine devices (IUDs) and contraceptive implants that are placed under the skin, both of which are highly effective, were linked with the lowest risk of blood clots in these higher-risk women. Hormonal contraceptives boost women's risk for clots, which can lead to heart attack and strokes.

U.S. patent agency to weigh rival claims on gene-editing technology
6 Dec 2016 at 8:16am
(Corrects company name to Editas Medicine from Editas Pharmaceuticals in paragraph 15) By Brendan Pierson (Reuters) - The U.S. patent agency on Tuesday will hear arguments in a heated dispute over who was first to invent a revolutionary gene-editing technology known as CRISPR. Hundreds of millions of dollars may be at stake, as the technology promises commercial applications in treating genetic diseases, engineering crops, and other areas. CRISPR works as a type of molecular scissors that can trim away unwanted parts of the genome, and replace them with new stretches of DNA.

Indonesia pledges to protect peatlands to fight climate change, haze
6 Dec 2016 at 7:45am
By Coco Liu HONG KONG (Thomson Reuters Foundation) - Environmental activists hailed on Tuesday Indonesia's ban on converting peatlands into plantations but said enforcement was critical to reducing annual fires that shroud parts of Southeast Asia in choking haze. Indonesia announced on Monday that companies were banned from turning peatlands into palm oil and other types of plantations, and must restore peatlands they have degraded. When peatlands are drained or cleared by fire to make way for plantations, the carbon is released into the atmosphere.

Factbox: Contenders, picks for key jobs in Trump's administration
6 Dec 2016 at 6:51am
(Reuters) - U.S. President-elect Donald Trump said on Monday he would nominate retired neurosurgeon Ben Carson, a presidential rival-turned-supporter to serve as Department of Housing and Urban Development secretary. Below are people mentioned as contenders for senior roles as Trump works to form his administration before taking office on Jan. 20, according to Reuters sources and media reports. See the end of list for posts already filled. ...


Emaciated Yemeni woman now smiles but recovery patchy
6 Dec 2016 at 6:28am

By Mohammed Ghobari SANAA (Reuters) - Images of 18-year-old Saida Ahmad Baghili's emaciated body shocked the world and turned a spotlight on the worsening humanitarian crisis across war-torn Yemen. Now, after weeks of specialist hospital care in the capital Sanaa, though she can still barely speak and sometimes finds eating more difficult than ever, she can at least smile.


Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com. CityRegions.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright 2012 GroupWeb Media LLC. All Rights Reserved.


GroupWeb Media Network
AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | iCameroon.com | i-Canada-News.Com | i-SoftwareNews.com | iT-NewsWire.Com
| InvestorsNewsDesk.Com | i-TravelNewsWire.Com | LegalLaw247.com | Medical-NewsWire.com | MiningNewsWire.net | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | Shopping-NewsWire.com | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com |
Medical-Newswire.com - Medicl Newswire and Press Release service of GroupWeb Media LLC